Do large, simple trials have a place in the evaluation of AIDS therapies?
Would trials enrolling large numbers of patients and that would require the collection of a relatively small amount of baseline and follow-up data be useful in evaluating treatments for AIDS? It seems worth considering whether widely available large, simple trials, especially those focused on optimizing dosage regimens of existing drugs, could serve the dual purpose of answering important patient management questions and improving the access of indigent populations to marketed therapies.